29 slides from Dr. Lal Pathlabs's earnings presentation, Feb 10, 2022
Slide 1: Exchange filing cover letter for Q3 FY22 presentation
February 10, 2022 National Stock Exchange of India BSE Limited Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Sandra Kurla Complex Sandra (E) Dalal Street Mumbai - 400 051. Mumbai- 400001 Subject: Investors Presentation on Unaudited Financi
Slide 2: Q3 FY22 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q3 FY22 Results Presentation Feb 10, 2022
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 4 Overview of Dr. Lal PathLabs 5 Key Performance Highlights 7 Financials 9 Financial Highlights 10 Operating Highlights 11 Management Commentary 12 Corporate Overview 13 Shareholding 27 Contact Us 28 DISCLAIMER: This presentation may contain ‘forward-
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance India’s Leading & Trusted 15% 22% 200% Diagnostics Company Largest* 3 Year Revenue 3-Year PAT Equity Dividend CAGR CAGR for FY 20-21 diagnostics 70+ years of experience chain in the in the field of diagnostics country with ~86% Rs. 331 crore (Net) PAN India ROCE Cash &
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Pan-India Unique and Established integrated successful brand coverage Varied Offerings operating model 231 clinical labs Well-positioned (including National Reference Lab at Catalogue of 471 test Scalable model in one of the Established consumer Delhi and Regional panels
Slide 7: Q3 FY22 Snapshot
Q3 FY22 Snapshot 9.8% INR 496.9 Cr 28.1% INR 438.1 Cr Revenues Non Covid Revenues Margin 21.1% 6.6 Mn 28.5% INR 141.8 Cr Patients Normalised EBITDA* 25.3% 16.9 Mn Margin 16.8% INR 83.6 Cr Samples Normalised PAT** * Normalised EBITDA excl. RSU, CSR & Onetime acquisition expenses **Normalised PAT excl
Slide 8: Key Performance Highlights
Key Performance Highlights In Q3 FY22: • Revenues up by 9.8% Y-o-Y to Rs. 496.9 crore • Normalised EBITDA* came in at Rs. 141.8 crore, margin of 28.5% • Normalised Profit After Tax** at Rs. 83.6 crore, margin of 16.8% Net Cash and Cash Equivalents at Rs. 331 crore as on December 31, 2021 Witnessed s
Slide 9: Non-COVID, COVID & Allied Revenue
Non-COVID, COVID & Allied Revenue Rs. Cr. Total 452 431 607 498 497 448 438 374 386 342 105 81 74 13 43 41 37 49 16 6 8 4 10 2 8 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q3 FY22 Non COVID COVID* COVID Allied 1** COVID Allied 2*** *COVID includes RTPCR and Antibody tests; **COVID Allied 1 includes IL-6 & D-Di
Slide 10: Financials
Financials Particulars (Rs. Cr.) Q3 FY22 Q3 FY21 Gr % YTD Dec'21 YTD Dec'20 Gr % Revenue 496.9 452.4 9.8% 1,601.9 1,150.3 39.3% Expenditure 387.6 313.6 1,162.2 836.1 EBITDA 109.2 138.7 439.6 314.3 Stock based comp., CSR cost & 32.6 5.8 53.4 18.8 One time Acquisition Expenses Normalised EBITDA 141.8
Slide 11: Financial Highlights
Financial Highlights All figures in Rs. Crore Revenue Normalised EBITDA* Normalised PBT** Normalised PAT** Total & Non Covid 496.9 452.4 438.1 95.9 128.9 341.9 83.6 +28% 112.8 +10% 144.6 141.8 Margin Margin Margin Margin Margin Margin 28.5% 22.7% 21.2% 16.8% 32% 28.5% Q3 FY21 Q3 FY22 Q3 FY21 Q3
Slide 12: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +38 +1,552 +3,623 200 216 231 3,095 3,705 9,247 193 2,569 6,426 6,995 2,153 5,624 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 No. of Patients (Mn) No. of Samples (Mn) +43% +33% 47.7 49.7 51.9 17.6 19.4 20.3 20.
Slide 13: Management Commentary
Management Commentary Commenting on the results Commenting on the results Commenting on the results announcement, Dr. Om Manchanda, announcement, Mr. Bharath Uppiliappan, announcement, (Hony) Brig. Dr. Arvind Managing Director said: Chief Executive Officer said: Lal, Executive Chairman said: “The co
Slide 14: Corporate Overview
Corporate Overview
Slide 15: Vision, Mission & Values
Vision, Mission & Values VISION Customer First Be the most trusted healthcare partner, enabling healthier lives Ethics & Integrity VALUES Quality To be the undisputed market leader by providing accessible, affordable, timely and quality healthcare, Accountability diagnostics, applying insights and c
Slide 16: Vibrant Outlook
Vibrant Outlook Strongly develop Rest of India geographies, through Regional Reference Labs and cluster city approach for attractive markets Target to grow Evaluate best fit inorganic Deeper Penetration within the ahead opportunities in South & West North, East & Central Indian of the markets indust
Slide 17: DLPL Strategy for future growth
DLPL Strategy for future growth 1 2 Strengthen Expansion in Existing Offering Operations Expand 4 3 management of Geographic hospital based expansion and clinical laboratories Classification: Restricted 16
Slide 18: DLPL Strategy for future growth
DLPL Strategy for future growth Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city & cluster approach standards diagnostic t
Slide 19: Leveraging digital to make life easier for patient
Leveraging digital to make life easier for patient Logistics Lab Operations Business Digital Lab e-Commerce Mobile app Automation Automation Continuity Plan • Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model Kiosk for patients
Slide 20: Consistent investments in R&D
Consistent investments in R&D DSIR recognized In House R&D unit R&D Collaboration with marquee Successful commercialization of with an experienced team of institutions tests research scientists and doctors Jawaharlal Nehru University for development of diagnostics kit for detection of mycobacterium
Slide 21: Genevolve: The Genomics initiative
Genevolve: The Genomics initiative GENEVOLVE brings the dawn of a new era of Genomic testing! Tests are carried out using cutting edge technologies such as Genevolve: Genomics division Next Generation Sequencing focuses on Genetic testing (NGS), MLPA, ddPCR, FISH & Sanger Sequencing among others New
Slide 22: In-house adoption of Digital Histopathology
In-house adoption of Digital Histopathology Reporting of Digital Breast cancer Panels using AI based algorithms Digital Histopathology for remote routine reporting • Enhanced access to second opinion, synchronous review of slides Opportunities • Enhanced quality of reporting created by Digital •
Slide 23: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry 100+ Quality Risk based improvement Digitally enabled Real time quality solutions control quality meetings on a assurance daily basis with implemented for monitoring quality audits framework the network partners and trainings Best in the Industry CAP Profici
Slide 24: Best in class Logistics and Supply Chain management
Best in class Logistics and Supply Chain management Real Real time time service sample monitoring tracking Control tower Real time Field Automated Cash Productivity Executive collection and route tracking process planning with clients visibility Classification: Restricted 25
Slide 25: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Auto Routing engine to dynamically allocate the booking to nearest Real time phlebo visibility to the patient available phlebotomist Variable model which grows with Real time slot confirmation to patient business volume ECG at home service launched in
Slide 26: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Group Chief Financial Officer Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg Compa
Slide 27: Key Awards & Recognition
Key Awards & Recognition Dr. Om Manchanda honoured ICICI Lombard & CNBC EY Entrepreneur of The Data Quest Technology VC Circle Healthcare and awarded as ‘Healthcare TV18 India Risk Year 2019 – Life Award 2015 – Excellence Summit 2013 – Best Personality of the Year, 2020’ Management Awards 2020 Scien
Slide 28: Shareholding as of 31st December, 2021
Shareholding as of 31st December, 2021 29.0% FIIs, FPIS, Foreign Company & NRIs 55.2% Promoter and Promoter 11.5% Group Others 4.3% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well Classification: Restricted 27
Slide 29: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests